STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp. - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceuticals Holding news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.

One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.

The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.

Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.

For more information, visit Tonix Pharmaceuticals Holding Corp.

News

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces a registered direct offering of 14,666,666 shares of common stock and warrants with existing investors, aiming to raise capital for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.42%
Tags
offering
-
News

Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced that the FDA granted Rare Pediatric Disease Designation to TNX-2900, a proprietary magnesium-potentiated formulation of intranasal oxytocin, for the treatment of Prader-Willi syndrome in children and adolescents. This designation recognizes the significant unmet need for effective treatments for PWS, a genetic disorder causing life-threatening childhood obesity. The Company may receive a transferable Priority Review Voucher upon approval, potentially worth $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
-
News

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces ongoing Phase 2 studies of TNX-1900 and TNX-2900 for various disorders. The company presented a poster at the ACS Spring 2024 Meeting on novel oxytocin analogues for pain, eating disorders, and endocrine conditions. Intranasal oxytocin shows promise in reducing food intake and improving insulin sensitivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
News

Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces the selection of two contract manufacturing organizations for the commercial launch of Tonmya™, a potential new first-line, centrally acting non-opioid analgesic for fibromyalgia. Positive Phase 3 study results show significant pain reduction and improvements in sleep quality, fatigue, and overall fibromyalgia symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
News

Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces the transition to a fully integrated pharmaceutical company by April 1, 2024, following the acquisition of Zembrace SymTouch and Tosymra. The company will market these products through its subsidiary and prepare for the potential launch of Tonmya for fibromyalgia in 2025, pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
-
News

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. reported positive results from the second Phase 3 trial of Tonmya™ for fibromyalgia management. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024. In Japan, China, and most European countries, cyclobenzaprine is considered a New Chemical Entity. Tonix CEO will present at the 2024 BIO-Europe Spring Convention in Barcelona, Spain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
News

Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced positive Phase 3 RESILIENT study results for Tonmya in fibromyalgia treatment, meeting primary and all secondary endpoints with significant improvements in pain reduction, sleep quality, fatigue, and cognitive dysfunction. NDA submission expected in the second half of 2024 following FDA meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
clinical trial
-
News

Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces positive results from TNX-102 SL therapy studies for PTSD and acute stress reaction. The company's research paper highlights the potential of bedtime TNX-102 SL treatment in improving PTSD severity and sleep quality in military-related PTSD cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces EVERSANA as partner for the launch strategy of Tonmya, a potential first-line non-opioid analgesic for fibromyalgia. Positive Phase 3 trial results support NDA submission to FDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
News

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces promising results for TNX-1500, a third-generation anti-CD40L mAb with reduced thrombosis risk and potential peak sales exceeding €5B per year. TNX-1500 shows positive PK properties in animal studies, supporting monthly dosing, and has multiple potential indications in transplantation and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none

FAQ

What is the current stock price of Tonix Pharmaceuticals Holding (TNXP)?

The current stock price of Tonix Pharmaceuticals Holding (TNXP) is $0.19 as of November 22, 2024.

What is the market cap of Tonix Pharmaceuticals Holding (TNXP)?

The market cap of Tonix Pharmaceuticals Holding (TNXP) is approximately 38.2M.

What is the main focus of Tonix Pharmaceuticals Holding Corp.?

Tonix focuses on developing, licensing, and commercializing therapeutics to treat and prevent human diseases, with a primary focus on central nervous system disorders.

What is Tonmya?

Tonmya is a treatment developed by Tonix Pharmaceuticals aimed at addressing PTSD. It is one of the company's key projects.

What are TNX-601 and TNX-801?

TNX-601 (tianeptine oxalate) is a candidate for daytime treatment of PTSD and TNX-801 is a synthetic version of the horsepox virus, intended as a potential smallpox-preventing vaccine.

What is TNX-1500?

TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases.

Which institutions is Tonix Pharmaceuticals affiliated with?

Tonix has established partnerships with reputable institutions, including Massachusetts General Hospital, to support their research and development projects.

How can I get more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their official website, www.tonixpharma.com.

What areas of disease does Tonix Pharmaceuticals focus on?

Tonix focuses on central nervous system disorders, organ transplant rejection, autoimmunity, cancer, rare diseases, and infectious diseases.

What stage are TNX-601 and TNX-801 in?

Both TNX-601 and TNX-801 are at the pre-IND (Investigational New Drug) application stage.

Who can I contact for investor relations at Tonix Pharmaceuticals?

For investor relations, you can contact Jessica Morris at investor.relations@tonixpharma.com or Peter Vozzo at peter.vozzo@westwicke.com.

Who can I contact for media inquiries at Tonix Pharmaceuticals?

For media inquiries, you can contact Katie Dodge at kdodge@lavoiehealthscience.com.

Stock TNXP logo
Tonix Pharmaceuticals Holding Corp.

Nasdaq:TNXP

TNXP Rankings

#5006 Ranked by Market Cap
N/A Ranked by Dividends

TNXP Stock Data

38.16M
186.60M
0.17%
0.23%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHATHAM